Print page

DSM Signs Supply Agreement with Eisai for Sterile Products

pharmamanufacturing.com
03/05/2013

DSM Pharmaceutical Products announced the signing of a three-year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, for the production of sterile products.

The agreement covers the production of eribulin mesylate as well as other developmental drugs. President and CEO of DSM Pharmaceutical Products Alexander Wessels said, “We are delighted to be working with Eisai under a long-term agreement to serve markets globally for important human health treatments, bringing our expertise and reliability in sterile injectables and worldwide regulatory record to ensure market supply.”

DSM will be a supplier for eribulin mesylate to the U.S. market. Commercial production is anticipated to start in early 2013. Laura Parks, president of DSM Pharmaceuticals Inc., the finished dosage business of DSM, stated: “It has been an honor to work with Eisai through the launch into commercial supply of eribulin mesylate and to continue to support the development of other products. Combining the expertise of Eisai in developing innovative medicines with DSM’s strength in Good Manufacturing Practices (GMP), and supply chain management will provide critical high quality treatments for patients.”

DSM operates a 1.5-million-square-foot finished dosage facility in Greenville, N.C., with a broad range of capabilities in aseptic filling of liquid and freeze-dried cytotoxic and non-cytotoxic steriles, the manufacture of tablets and capsules, pharmaceutical development services, and clinical trial materials manufacturing for solid and injectable forms, and holds a range of regulatory approvals including the production of scheduled drugs.

Eisai is a research based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.

No financial details were disclosed.